KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients

Clin Transplant. 2011 May-Jun;25(3):E284-91. doi: 10.1111/j.1399-0012.2011.01417.x. Epub 2011 Mar 1.

Abstract

Recent genome-wide association studies identified single-nucleotide polymorphisms (SNPs) in the gene encoding the pore-forming subunit of the voltage-gated K+ channel (KCNQ1) as a risk factor for type 2 diabetes. Tacrolimus (Tac) increased the risk of new-onset diabetes after transplantation (NODAT). The aim of this study was to analyze the association between KCNQ1 variants and the risk for NODAT in kidney-transplanted patients who received Tac as primary immunosuppressor. We genotyped three common KCNQ1 SNPs in 145 Spanish patients who received a cadaveric kidney graft and developed NODAT in the first-year post-transplant (the NODAT group), and 260 patients who remained non-diabetics (non-NODAT). In addition, we searched for DNA variants in the whole KCNQ1 coding exons in these patients. SNP rs2237895 (genotype CC) was associated with an increased risk for NODAT in our population (p = 0.008; OR = 1.83, 95% CI = 1.14-2.93), independently of other risk factors as body mass index, recipient age, or tacrolimus dosage. Other KCNQ1 variants were not associated with NODAT in our patients. Our work supported a role for KCNQ1 gene variants as determinants of the risk of developing NODAT among Tac-treated patients.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 2 / etiology*
  • Female
  • Follow-Up Studies
  • Genome-Wide Association Study
  • Genotype
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • KCNQ1 Potassium Channel / genetics*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide / genetics*
  • Postoperative Complications*
  • Prognosis
  • Risk Factors
  • Survival Rate
  • Tacrolimus / adverse effects*

Substances

  • Immunosuppressive Agents
  • KCNQ1 Potassium Channel
  • KCNQ1 protein, human
  • Tacrolimus